Clinical Trials
225 trialsORCHID
Fudan University
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
University of California, San Francisco
SHIVA
Institut Curie
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
INNOVATION
European Organisation for Research and Treatment of Cancer - EORTC
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Memorial Sloan Kettering Cancer Center
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
ADAPT; T-DM1
West German Study Group
ADAPT
West German Study Group
met-HEReMYTA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
MyTACTIC
Genentech, Inc.
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
TOUCH
ETOP IBCSG Partners Foundation
monarcHER
Eli Lilly and Company
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Seagen Inc.
NeoTOP
UNICANCER
MIMOSA
The Netherlands Cancer Institute
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
MODUL
Hoffmann-La Roche
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Case Comprehensive Cancer Center
PATRICIA II
SOLTI Breast Cancer Research Group
TP-II
Palleos Healthcare GmbH
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
PHranceSCa
Hoffmann-La Roche
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NYU Langone Health
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
R2D2
Intergroupe Francophone de Cancerologie Thoracique
HER3+
Cancer Insight, LLC
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
University of Nebraska
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
HER2CLIMB
Seagen Inc.
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Yale University
Keyriched-1
West German Study Group
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Spanish Breast Cancer Research Group